Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Kuur Therapeutics, Inc.. (3/10/20). "Press Release: Kuur Therapeutics Launches to Develop and Commercialize “Off-the-Shelf” CAR-NKT Cell Therapies Targeting Hematological and Solid Tumors". Houston, TX.

Organisations Organisation Kuur Therapeutics Inc.
  Group Athenex (Group)
  Organisation 2 Schroder Adveq
  Group Schroders (Group)
Products Product NK cell therapy (natural killer cell therapy)
  Product 2 CAR-T technology (Chimeric Antigen Receptor T-Cell technology)
Index term Index term Kuur Therapeutics–SEVERAL: investment, 202003 financing round with IP Group + Baylor College of Medicine + Schroeder Adveq
Persons Person Boyle, Kevin S., Sr. (Kuur Therapeutics 202003– CEO before Cell Medica 201802– CFO based in Houston TX)
  Person 2 Jenkins, Annalisa (TransCelerate BioParma 201402 Chair of Board of Directors before Merck Serono + BMS)
     


> New investments from IP Group, Baylor College of Medicine (BCM) and Schroeder Adveq

> Proceeds to fund phase 1 studies in both CD19 malignancy and neuroblastoma, as well as preclinical work in hepatocellular carcinoma

> Kevin S Boyle, Sr, named CEO of the new business

> Allogeneic natural killer T cell-based therapy platform could overcome challenges of current autologous CAR-T therapies


Kuur Therapeutics today announced the launch of its new business in partnership with Baylor College of Medicine and Baylor’s Center for Cell and Gene Therapy. Houston-based Kuur Therapeutics will advance the work of its predecessor, Cell Medica, to develop anti-cancer therapies using its innovative chimeric antigen receptor natural killer T cell (CAR-NKT) therapy platform.

IP Group, Baylor College of Medicine and Schroeder Adveq are investing to support two phase 1 studies: GINAKIT 2 (autologous CAR-NKT cells in neuroblastoma) and ANCHOR (allogeneic CAR-NKT cells in CD19 malignancy). The ongoing GINAKIT2 study is now enrolling patients at the third dose level and the ANCHOR study IND has recently been approved by the FDA, with first patient treatment expected in 1H 2020. The funding will also support the preclinical development of an allogeneic CAR-NKT product for treatment of hepatocellular carcinoma, ahead of an IND submission anticipated in 1H 2021.

In conjunction with the new investment, Kevin S Boyle, Sr, was named CEO of Kuur, succeeding Chris Nowers. Mr Boyle joined Cell Medica as CFO in February 2018. Kevin previously held senior finance roles at both NASDAQ-listed and private equity backed companies. He is an accomplished capital markets professional, having raised over $2.0 billion in equity and debt capital.

Kuur’s novel CAR-NKT platform is a next-generation technology of engineered immune cells with enhanced functions for the treatment of hematological and solid tumors. It utilizes the unique properties of NKT cells, a specialized type of innate lymphocyte, which shares properties with both T and NK cells. This platform, developed in the laboratory of Baylor Principal Investigator Leonid Metelitsa, is exclusively licensed to Kuur by its partner and collaborator, Baylor College of Medicine.

Annalisa Jenkins, Chair of Kuur’s Board, said: “We are fortunate to have Kevin step up to the role of CEO. He will act as a change agent, leading the company during a crucial period for our clinical trials and working to secure the additional capital required to progress our two lead CAR-NKT products through the clinic.

“The Board would also like to thank Chris for his exceptional leadership during a transition period that has resulted in a company on the right path forward for its investors, with a focus on its important collaborations.”

Kevin S Boyle, Sr, Kuur’s CEO, said: “I am excited to lead Kuur Therapeutics at such a pivotal moment. We are making final preparations to take our off-the-shelf program into the clinic and believe the allogeneic approach holds huge promise for unlocking the potential of CAR therapies for large patient populations. Compared with patient-specific autologous CAR products, it is immediately available for treatment and less expensive to manufacture.”

Leonid S. Metelitsa, BCM Principal Investigator, said: “My goal is to make a difference in the lives of cancer patients, especially children, and I’m excited to be working with the Kuur team to make this goal a reality. I believe that the NKT-cell platform technology, developed in my laboratory and progressed to first-in-human clinical testing in close collaboration with colleagues at BCM and Texas Children’s Hospital, offers a unique route to next-generation off-the-shelf CAR therapies for a broad range of malignancies.”

   
Record changed: 2021-05-08

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Athenex (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top